Answers are grounded in this paper and cite their sources.
The emergence of multi-omics technologies has enabled the integration of genomic, transcriptomic, epigenomic, proteomic, and metabolomic data to characterize the molecular complexity of cancer. Single-cell and spatial profiling further resolve intratumoral heterogeneity, cell–cell interactions, and the microenvironmental determinants of therapeutic responses. In parallel, artificial intelligence (AI) provides computational approaches for integrating these heterogeneous data types across target identification, drug response prediction, toxicity assessment, and drug-combination modeling. Across these domains, the available evidence indicates that multi-omics integration is most beneficial when the included layers provide complementary biological information; that single-cell and spatial omics analyses reveal treatment-resistant populations and niches but remain largely research-grade and thus not ready for routine clinical deployment; and that although foundation models support some representation-learning tasks, their advantages in perturbation-response prediction require confirmation via stringent evaluation. By distinguishing externally validated advances from retrospective proof-of-concept studies, we provide a practical framework for evaluating the translational readiness of AI-driven multi-omics tools in precision oncology.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: